Last reviewed · How we verify

Suprane (desflurane), Baxter

Medical University of Gdansk · FDA-approved active Small molecule Under review Quality 0/100

Suprane (desflurane), Baxter is a Volatile anesthetic Small molecule drug developed by Medical University of Gdansk. It is currently FDA-approved for Induction and maintenance of general anesthesia in adults and children. Also known as: desflurane.

Desflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.

Desflurane is a small molecule that acts as a positive modulator of the glycine receptor (alpha-1/beta). It is used in anesthesia, particularly with the use of a laryngeal mask airway, and has been studied in various clinical trials for conditions such as postoperative cognitive dysfunction and mechanical ventilation complications.

At a glance

Generic nameSuprane (desflurane), Baxter
Also known asdesflurane
SponsorMedical University of Gdansk
Drug classVolatile anesthetic
TargetGABA-A receptor, NMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Desflurane is a halogenated ether volatile anesthetic that acts on multiple ion channels and neurotransmitter receptors in the brain to produce rapid anesthesia and unconsciousness. It enhances the activity of inhibitory GABA-A receptors while simultaneously blocking excitatory NMDA glutamate receptors, resulting in profound CNS depression. The exact molecular mechanism remains incompletely understood but involves modulation of multiple neuronal targets rather than a single receptor.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Suprane (desflurane), Baxter

What is Suprane (desflurane), Baxter?

Suprane (desflurane), Baxter is a Volatile anesthetic drug developed by Medical University of Gdansk, indicated for Induction and maintenance of general anesthesia in adults and children.

How does Suprane (desflurane), Baxter work?

Desflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.

What is Suprane (desflurane), Baxter used for?

Suprane (desflurane), Baxter is indicated for Induction and maintenance of general anesthesia in adults and children.

Who makes Suprane (desflurane), Baxter?

Suprane (desflurane), Baxter is developed and marketed by Medical University of Gdansk (see full Medical University of Gdansk pipeline at /company/medical-university-of-gdansk).

Is Suprane (desflurane), Baxter also known as anything else?

Suprane (desflurane), Baxter is also known as desflurane.

What drug class is Suprane (desflurane), Baxter in?

Suprane (desflurane), Baxter belongs to the Volatile anesthetic class. See all Volatile anesthetic drugs at /class/volatile-anesthetic.

What development phase is Suprane (desflurane), Baxter in?

Suprane (desflurane), Baxter is FDA-approved (marketed).

What are the side effects of Suprane (desflurane), Baxter?

Common side effects of Suprane (desflurane), Baxter include Emergence agitation, Postoperative nausea and vomiting, Airway irritation, Hypotension, Tachycardia.

What does Suprane (desflurane), Baxter target?

Suprane (desflurane), Baxter targets GABA-A receptor, NMDA receptor and is a Volatile anesthetic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing